BioSpace News Archive

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) announced today that the United States (“U.S.”) Food and Drug Administration (FDA) has granted Fast Track designation based on nonclinical and clinical data for the development of ASP5354,

Allergan, an AbbVie (NYSE: ABBV) company, today announced the Phase 3 GEMINI 1 and 2 clinical trials evaluating the efficacy, safety and tolerability of investigational AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of symptoms associated with presbyopia, met their primary efficacy endpoint

I-Mab (the “Company”) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences in November. Details of the conferences and management presentation are as follow

MMI SpA, an Italian company dedicated to improving clinical outcomes for patients undergoing microsurgery, announced today the CE Mark, launch and first human use of its Symani® Surgical System in Europe for open microsurgical procedures.

Rarecells, Inc. (USA), a leading Liquid Biopsy company, is pleased to announce that National Institute of Integrative Medicine’s (Melbourne, Australia) researchers obtained striking results in a group of Australian men using the ISET® test for early prostate cancer diagnosis through the detection of Prostate-Specific Antigen (PSA) positive Circulating Tumor Cells (CTC).

Aran Biomedical Teoranta, a provider of outsourced design, development and manufacturing services for implantable devices, today announced the opening of its dedicated braiding centre at its Global Headquarters in Spiddal, Galway, Ireland

Flagship Pioneering today announced the unveiling of Senda Biosciences, a therapeutics platform company leveraging unprecedented insights into the molecular connections between humans and coevolved nonhuman species.

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the following conferences: Credit Suisse 29 th Annual Virtual Healthcare Conference Wednesday, November 11 th at 9:30 a.m. ET Barclays Virtual Gene Editing & Gene Therapy Summit Monday, November 16 th

Castle Creek Biosciences, Inc, a privately-held, clinical-stage cell and gene therapy company leveraging its proprietary fibroblast technology platform to develop and commercialize innovative personalized therapies for underserved disorders with high unmet medical needs, today announced the first patient has been dosed in the DeFi-RDEB Phase 3 clinical trial evaluating debcoemagene autoficel (D-Fi

MAXREFDES104# is a wrist form factor reference design ready to collect blood oxygen, ECG, heart rate, body temperature and activity data